Affiliation:
1. IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE
Abstract
Aim: To identify the medical management determinants of the maxillofacial precancerous and benign diseases malignancy
Materials and Methods: 150 people with maxillofacial cancer and 100 people with precancerous and benign diseases of the same localization were interviewed.
Results: There were revealed: a low percentage of detection during check-up (10.2-15.8%), more than a third of cases (35.8-37.4%) are diagnosed by chance; not all patients undergo histological verification of the diagnosis (25.7% in cancerous and 43.2% in precancerous and benign diseases); not all are under follow up observation (24.7-27.7%). The risk of precancerous and benign diseases malignancy is the highest at 40-59 years of age (OR=4.4; 95% CI: 1.9-10.5), andalso increases with the duration of the disease for more than 5 years (2.2; 1.2-4.10 ), in patients who didn’t undergo histological verification (2.2; 1.3-3.8), don’t follow doctors’ recommendation on visits and treatment (2.4; 1.4-4.1), don’t trust doctors and are dissatisfied with medical care (2.1; 1.3-3.6). The risk groups of the maxillofacial oncological, precancerous and benign diseases are men, who are 1.5 times more likely to suffer from them than women and are characterized by lower medical care activity. The risk factors of the maxillofacial precancerous and benign diseases malignancy are low financial (4.6; 1.7-12.4) and territorial (3.3; 1.1-10.3) accessibility of medical care, including dental care (2.8; 1.6-4.8).
Conclusions: It is necessary to improve the prevention and medical care in order to advance the early detection of maxillofacial cancer, taking into account the established medical management determinants of malignancy.
Reference27 articles.
1. 1. Kocarnik JM, Compton K, Dean FE et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncology. 2022;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987.
2. 2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(4):7-33. doi: 10.3322/caac.21654.
3. 3. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249. doi: 10.3322/caac.21660.
4. 4. Bray F, Laversanne M, Weiderpass E, Soerjomatram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029-3030. doi: 10.1002/cncr.33587.
5. 5. World Medical Organization. Cancer prevention and control in the context of an integrated approach. Seventh world medical assembly. Agenda item 15.6. WHA70.12, 31 May 2017 https://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R12-en.pdf [date access 21.06.2023];